CytoMed Therapeutics Limited

$1.32+9.09%(+$0.11)
TickerSpark Score
53/100
Mixed
55
Valuation
20
Profitability
55
Growth
84
Health
50
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GDTC research report →

52-Week Range21% of range
Low $0.68
Current $1.32
High $3.68

Companyw2.cytomed.sg

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers.

CEO
Chee Kong Choo
IPO
2023
Employees
43
HQ
Singapore, SG

Price Chart

-34.33% · this period
$2.69$1.71$0.72May 20Nov 18May 20

Valuation

Market Cap
$15.62M
P/E
-3.44
P/S
36.66
P/B
2.38
EV/EBITDA
-3.28
Div Yield
0.00%

Profitability

Gross Margin
-63.95%
Op Margin
-1075.12%
Net Margin
-1062.06%
ROE
-75.27%
ROIC
-62.45%

Growth & Income

Revenue
$319.20K · 513.79%
Net Income
$-3,916,834 · -107.99%
EPS
$-0.33 · -106.25%
Op Income
$-4,519,770
FCF YoY
-46.22%

Performance & Tape

52W High
$3.68
52W Low
$0.68
50D MA
$1.00
200D MA
$1.50
Beta
-0.17
Avg Volume
16.14K

Get TickerSpark's AI analysis on GDTC

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 18, 26Yew Chak Huaother0
Mar 18, 26Leong Mark Kei Weiother0
Mar 18, 26Choo Chee Kongother0
Mar 18, 26Choo Chee Kongother0
Mar 18, 26Choo Chee Kongother0
Mar 18, 26TAN YOONG YINGother0
Mar 18, 26Goh Yvonneother0

Our GDTC Coverage

We haven't published any research on GDTC yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate GDTC Report →

Similar Companies